Condition
Hormone Receptor Positive Tumor
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 30 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
30 shownA Study of the TheraBionic P1 Device in Breast CancerNCT07218432 · 2026-10-01
RECRUITINGStudy of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsNCT07524322 · 2026-06-01
RECRUITINGA Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast CancerNCT07227831 · 2026-01-16
RECRUITINGPhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26
RECRUITINGAdherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast CancerNCT06650423 · 2025-01-05
RECRUITINGOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerNCT05735080 · 2023-03-28
RECRUITINGElacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerNCT05982093 · 2023-02-03
RECRUITINGSNF Platform Study of HR+/ HER2-advanced Breast CancerNCT05594095 · 2022-12-30
RECRUITINGFudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 2022-11-01
RECRUITINGI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerNCT01042379 · 2010-03-01
RECRUITINGFirst-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid TumorsNCT05759949 · 2023-03-29
COMPLETEDImpact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast CancerNCT04352777 · 2020-09-14
COMPLETEDStudy of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerNCT04134884 · 2020-04-01
COMPLETEDPyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerNCT04088110 · 2019-11-01
UNKNOWNLimited Adjuvant Endocrine Therapy for Low Risk Breast CancerNCT03917082 · 2019-09-23
ACTIVE_NOT_RECRUITINGPyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBCNCT03910712 · 2019-06-01
UNKNOWNAromatase Inhibitor and Durvalumab in Postmenopausal Breast CancerNCT03874325 · 2019-04-26
TERMINATEDPALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)NCT03809988 · 2019-04-05
COMPLETEDOpera® for Aromatase Inhibitor-related Arthralgia Management (AIA)NCT04161833 · 2018-11-01
COMPLETEDEstablishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast CancerNCT03904173 · 2018-10-29
ACTIVE_NOT_RECRUITINGBiomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast CancerNCT03691311 · 2018-07-05
UNKNOWNRole of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast CancerNCT03407768 · 2018-07-01
COMPLETEDRibociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First LineNCT03462251 · 2018-05-24
COMPLETEDA Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.NCT03906669 · 2018-03-20
UNKNOWNPhase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast CancerNCT03409198 · 2018-01-21
COMPLETEDStudy in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantNCT02894398 · 2016-09-06
COMPLETEDFulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerNCT02404051 · 2015-12-01
UNKNOWNNeoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive TumorsNCT02592083 · 2015-10-01
ACTIVE_NOT_RECRUITINGA Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast CancerNCT02441946 · 2015-08-01
COMPLETEDDose EScalation Induction of EvERolimusNCT02387099 · 2015-05-01
COMPLETEDCommon interventions
FulvestrantDRUG6AbemaciclibDRUG4PalbociclibDRUG4LetrozoleDRUG3PyrotinibDRUG3TrastuzumabDRUG3AnastrozoleDRUG2ApatinibDRUG2Aromatase InhibitorsDRUG2CyclophosphamideDRUG2DalpiciclibDRUG2EverolimusDRUG2ExemestaneDRUG2FamitinibDRUG2FluzoparibDRUG2GoserelinDRUG2SHR-A1811DRUG2SHR-A1921DRUG23 weeks Conventional Everolimus DosingDRUG13 weeks Dose Induction of EverolimusDRUG19MW2821DRUG1ABT-888DRUG1AKT inhibitorDRUG1AmcenestrantDRUG1Amcenestrant + AbemaciclibDRUG1
Leading sponsors
Barbara Ann Karmanos Cancer Institute
2
Fudan University
2
iOMEDICO AG
2
Oslo University Hospital
2
Relay Therapeutics, Inc.
2
Azienda Ospedaliero-Universitaria Careggi
1
British Columbia Cancer Agency
1
Consorzio Oncotech
1
Duke University
1
Eli Lilly and Company
1
Fuzhou General Hospital
1
GBG Forschungs GmbH
1
H. Lee Moffitt Cancer Center and Research Institute
1
Incyclix Bio
1
Institut Català d'Oncologia
1
Trial status mix
COMPLETED11
RECRUITING10
UNKNOWN5
ACTIVE_NOT_RECRUITING3
TERMINATED1
Phase mix
PHASE217
NA4
PHASE14
PHASE33
EARLY_PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.